Department of Urology, G. Hatzikosta General Hospital, 45001 Ioannina, Greece.
Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
Curr Oncol. 2022 Feb 23;29(3):1309-1315. doi: 10.3390/curroncol29030111.
(1) Background: Following radical prostatectomy (RP), the absence of a demonstrable tumor on the specimen of a previously histologically proven malignancy is known as the pT0 stage. The aim of our present study is to perform a narrative review of current literature in order to determine the frequency and oncological outcomes in patients with pT0 disease. (2) Methods: A narrative review of all available literature was performed. (3) Results: The incidence of pT0 ranges between 0.07% and 1.3%. Predictors of the pT0 stage are only a single biopsy core with low-grade cancer, a cancer length not exceeding 2 mm and a high prostate volume. Biochemical recurrence ranges between 0 and 11%. (4) Conclusions: The absence of malignancy in the RP specimen despite a previous positive biopsy is a rare and unpredictable finding. Although the prognosis is considered to be excellent in most of the cases, a continued close follow-up is warranted.
(1) 背景：在根治性前列腺切除术（RP）后，在先前组织学证实为恶性肿瘤的标本上未发现肿瘤，称为 pT0 期。我们目前的研究旨在对现有文献进行叙述性综述，以确定 pT0 疾病患者的频率和肿瘤学结果。
(2) 方法：对所有可用文献进行叙述性综述。
(3) 结果：pT0 的发生率在 0.07%至 1.3%之间。pT0 期的预测因素仅为单个活检核心伴有低级别癌症、癌症长度不超过 2 毫米和高前列腺体积。生化复发率在 0 至 11%之间。
(4) 结论：尽管先前的活检呈阳性，但在 RP 标本中未发现恶性肿瘤是一种罕见且不可预测的发现。尽管大多数情况下预后被认为是良好的，但仍需要密切随访。
